The Impact of Quetiapine on the Drug Abuse Patterns of Addicted Schizophrenic Patients
- Conditions
- SchizophreniaSubstance Use Disorders
- Registration Number
- NCT00295412
- Lead Sponsor
- Université de Montréal
- Brief Summary
The lifetime of substance use disorders in schizophrenia is close to 50%. Substance abuse in schizophrenia is associated with negative consequences. Unfortunately, there no clear guidelines for the pharmacological treatment of this dual diagnosis population. Preliminary results suggest that second-generation antipsychotic drugs (mainly clozapine) may relieve drug cravings in schizophrenia. We performed a 12-week pilot study to evaluate the impact of quetiapine, a second-generation antipsychotic, on substance abuse parameters, psychiatric symptoms and side effects in patients schizophrenia and comorbid substance use disorders. Our expectation was a 20 % decrease in drug cravings from baseline to end-point.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
- Patients with as schizophrenia spectrum disorder
- Patients with a comorbid substance use disorder
- Patients already on quetiapine or clozapine
- Patients hospitalized or acutely ill
- Total score lower than 65 on the PANSS
- Pregnancy
- Female subjects of childbearing potential without adequate contraception
- Abnormal liver function (hepatic enzymes more than 3 times the upper normal limits)
- Any clinically meaningful unstable renal, hepatic, cardiovascular, respiratory, cerebrovascular disease or other serious, progressive physical disease.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Centre de recherche Fernand-Seguin
🇨🇦Montreal, Quebec, Canada